Literature DB >> 15199381

Noninvasive diagnosis of the 3243A > G mitochondrial DNA mutation using urinary epithelial cells.

Martina T McDonnell1, Andrew M Schaefer, Emma L Blakely, Robert McFarland, Patrick F Chinnery, Douglass M Turnbull, Robert W Taylor.   

Abstract

The 3243A > G mutation is one of the most frequently observed mutations of mitochondrial DNA (mtDNA), and is associated with numerous clinical presentations including mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS), progressive external ophthalmoplegia (PEO) and diabetes and deafness. The routine diagnosis of the 3243A > G mutation in blood is difficult as mutation levels are known to decrease in this tissue over time, while in some patients it may be absent. We have directly compared the levels of the 3243A > G mutation in skeletal muscle, blood and urinary epithelial cells in 18 patients and observed a striking correlation between the mutation load in postmitotic muscle and urinary epithelium, a mitotic tissue. These data strongly support the use of urinary epithelial cells as the tissue of choice in the noninvasive diagnosis of the 3243A > G mutation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15199381     DOI: 10.1038/sj.ejhg.5201216

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  20 in total

Review 1.  A diagnostic algorithm for metabolic myopathies.

Authors:  Andres Berardo; Salvatore DiMauro; Michio Hirano
Journal:  Curr Neurol Neurosci Rep       Date:  2010-03       Impact factor: 5.081

2.  Depletion of mitochondrial DNA in leucocytes harbouring the 3243A->G mtDNA mutation.

Authors:  Angela Pyle; Robert W Taylor; Steve E Durham; Marcus Deschauer; Andrew M Schaefer; David C Samuels; Patrick F Chinnery
Journal:  J Med Genet       Date:  2006-09-01       Impact factor: 6.318

3.  Tissue specific distribution of the 3243A->G mtDNA mutation.

Authors:  A L Frederiksen; P H Andersen; K O Kyvik; T D Jeppesen; J Vissing; M Schwartz
Journal:  J Med Genet       Date:  2006-02-20       Impact factor: 6.318

4.  Increased Prevalence of Hypertension in Young Adults with High Heteroplasmy Levels of the MELAS m.3243A>G Mutation.

Authors:  Fady Hannah-Shmouni; Sandra Sirrs; Michelle M Mezei; Paula J Waters; Andre Mattman
Journal:  JIMD Rep       Date:  2013-07-12

Review 5.  Monogenic diabetes and pregnancy.

Authors:  Rinki Murphy
Journal:  Obstet Med       Date:  2015-06-29

6.  Longitudinal changes of mtDNA A3243G mutation load and level of functioning in MELAS.

Authors:  Mahsa Mehrazin; Sara Shanske; Petra Kaufmann; Ying Wei; Jorida Coku; Kristin Engelstad; Ali Naini; Darryl C De Vivo; Salvatore DiMauro
Journal:  Am J Med Genet A       Date:  2009-02-15       Impact factor: 2.802

7.  Maternally inherited mitochondrial DNA disease in consanguineous families.

Authors:  Charlotte L Alston; Langping He; Andrew A Morris; Imelda Hughes; Christian de Goede; Douglass M Turnbull; Robert McFarland; Robert W Taylor
Journal:  Eur J Hum Genet       Date:  2011-06-29       Impact factor: 4.246

8.  Urine heteroplasmy is the best predictor of clinical outcome in the m.3243A>G mtDNA mutation.

Authors:  R G Whittaker; J K Blackwood; C L Alston; E L Blakely; J L Elson; R McFarland; P F Chinnery; D M Turnbull; R W Taylor
Journal:  Neurology       Date:  2009-02-10       Impact factor: 9.910

9.  Prevalence and progression of diabetes in mitochondrial disease.

Authors:  R G Whittaker; A M Schaefer; R McFarland; R W Taylor; M Walker; D M Turnbull
Journal:  Diabetologia       Date:  2007-07-26       Impact factor: 10.122

Review 10.  Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society.

Authors:  Sumit Parikh; Amy Goldstein; Mary Kay Koenig; Fernando Scaglia; Gregory M Enns; Russell Saneto; Irina Anselm; Bruce H Cohen; Marni J Falk; Carol Greene; Andrea L Gropman; Richard Haas; Michio Hirano; Phil Morgan; Katherine Sims; Mark Tarnopolsky; Johan L K Van Hove; Lynne Wolfe; Salvatore DiMauro
Journal:  Genet Med       Date:  2014-12-11       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.